{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:24:50Z","timestamp":1769117090809,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.japh.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T17:03:38Z","timestamp":1536771818000},"page":"679-681","source":"Crossref","is-referenced-by-count":3,"title":["A unique case of buffalo hump after prolonged use of spironolactone"],"prefix":"10.1016","volume":"58","author":[{"given":"Timothy R.","family":"Hudd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pirneeka","family":"Chugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Zaiken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2018.07.005_bib1","series-title":"Aldactone (spironolactone) [prescribing information]","year":"2018"},{"issue":"3","key":"10.1016\/j.japh.2018.07.005_bib2","first-page":"37","article-title":"Oral spironolactone in post-teenage female patients with acne vulgaris practical considerations for the clinician based on current data and clinical experience","volume":"5","author":"Kim","year":"2012","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"1","key":"10.1016\/j.japh.2018.07.005_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactone: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.japh.2018.07.005_bib4","series-title":"Diuretic Agents: Clinical Physiology and Pharmacology","first-page":"630","article-title":"Metabolic derangements associated with diuretic use: insulin resistance, dyslipidemia, hyperuricemia, and androgenic effects","author":"Toto","year":"1997"},{"issue":"15","key":"10.1016\/j.japh.2018.07.005_bib5","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1001\/jama.2018.2611","article-title":"Evaluation and treatment of hirsutism in premenopausal women","volume":"319","author":"Mimoto","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.japh.2018.07.005_bib6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jc.2018-00241","article-title":"Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline","volume":"103","author":"Martin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.japh.2018.07.005_bib7","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00266-006-0081-0","article-title":"Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians","volume":"30","author":"Sato","year":"2006","journal-title":"Aesth Plast Surg"},{"issue":"2","key":"10.1016\/j.japh.2018.07.005_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijwd.2016.12.002","article-title":"Spironolactone for the treatment of acne in women, a retrospective study of 110 patients","volume":"3","author":"Charny","year":"2017","journal-title":"Int J Womens Dermatol"},{"issue":"11","key":"10.1016\/j.japh.2018.07.005_bib9","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.japh.2018.07.005_bib10","series-title":"Greenspan\u2019s Basic and Clinical Endocrinology","article-title":"Glucocorticoids and adrenal androgens [chapter 9]","author":"Carroll","year":"2018"},{"issue":"9996","key":"10.1016\/j.japh.2018.07.005_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.japh.2018.07.005_bib12","series-title":"Taber\u2019s Cyclopedic Medical Dictionary","author":"Venes","year":"2017"},{"key":"10.1016\/j.japh.2018.07.005_bib13","first-page":"29","article-title":"Non-surgical reduction of buffalo hump deformity: case report and literature review","volume":"1","author":"Rauso","year":"2011","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"5418","key":"10.1016\/j.japh.2018.07.005_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/bmj.2.5418.1201-c","article-title":"Spironolactone and plasma cortisol","volume":"2","author":"Metcalf","year":"1964","journal-title":"Br Med J"},{"issue":"21","key":"10.1016\/j.japh.2018.07.005_bib15","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1056\/NEJM197005212822128","article-title":"Plasma cortisol after spironolactone","volume":"282","author":"Simon","year":"1970","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.japh.2018.07.005_bib16","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cpt1973146992","article-title":"Spironolactone and plasma cortisol","volume":"14","author":"Dumlao","year":"1973","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.japh.2018.07.005_bib17","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jama.1970.03170110057016","article-title":"Plasma cortisol assay interference by spironolactone","volume":"211","author":"Lurie","year":"1970","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.japh.2018.07.005_bib18","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/jama.1973.03220220086027","article-title":"Blood \u201ccortisol\u201d levels from spironolactone","volume":"224","author":"Tashima","year":"1973","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.japh.2018.07.005_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure","volume":"160","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.japh.2018.07.005_bib20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.japh.2018.07.005_bib21","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s00125-004-1510-8","article-title":"Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes","volume":"47","author":"Davies","year":"2004","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.japh.2018.07.005_bib22","first-page":"3339","article-title":"The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans","volume":"83","author":"Young","year":"1998","journal-title":"J\u00a0Clin Endocr Metab"},{"issue":"1","key":"10.1016\/j.japh.2018.07.005_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.npp.1301217","article-title":"Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition","volume":"32","author":"Otte","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl 1","key":"10.1016\/j.japh.2018.07.005_bib24","doi-asserted-by":"crossref","first-page":"s141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.japh.2018.07.005_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(97)11443-X","article-title":"Buffalo hump in men with HIV-1 infection","volume":"351","author":"Lo","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.japh.2018.07.005_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319118303789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319118303789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T12:10:48Z","timestamp":1541679048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319118303789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1544319118303789"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2018.07.005","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}